RT Journal Article
SR Electronic
T1 Analysis of IL-4 Levels, IL-1α, Cortisol Hormone, and Blood Cell Number in Parkinson’s Disease Patients Undergoing Dance-based Movement Therapy: A Preliminary Study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.09.21.24314141
DO 10.1101/2024.09.21.24314141
A1 Marques, Karen Adriana Pastana
A1 Bahia, Gabriel Mesquita da Conceição
A1 Duarte, Juliana dos Santos
A1 Pinto, Denise da Silva
A1 Martins Filho, Arnaldo Jorge
A1 de Jesus Oliveira Batista, Evander
A1 Oliveira da Silva, Anderson Manoel Herculano
A1 Matos Oliveira, Karen Renata Herculano
A1 Krejcova, Lane Viana
A1 Bahia, Carlomagno Pacheco
YR 2024
UL http://medrxiv.org/content/early/2024/09/23/2024.09.21.24314141.abstract
AB Introduction The interplay between neuroinflammation and Parkinson’s disease (PD) is still unclear, although several studies suggest that neuroinflammation plays an important role in the pathophysiological pathways of neurodegenerative disorders. Dance-based movement therapy has been studied as an adjuvant treatment for PD symptoms by modulating some inflammatory interleukins and improving the overall effect of pharmacological treatments.Objective To evaluate the levels of Interleukin 4, Interleukin 1α, cortisol hormone, and blood cell total numbers in PD subjects undergoing dance-based movement therapy.Methods Twenty-five participants were selected for this study. Seventeen subjects diagnosed with PD were divided into two groups: PD group (n=8) and PD+dance group (n=9). Another group was composed of age-matched healthy controls (n=8). The dance-based movement therapy was performed twice a week for 50-60 minutes/session over six months.Results The serum IL-4 levels were significantly lower in the PD group when compared to the healthy group, while the PD+Dance group showed similar levels to the healthy group. The levels of IL-1α, cortisol, and blood cell count showed no statistical differences between groups.Conclusion Our results suggest that regular practice of dance-based movement therapy may induce a neuroprotective effect by modulating the levels of IL-4 in people with PD similarly to healthy participants.Trial registration The study was registered in the Brazilian registry of clinical trials: RBR-3bhbrb5.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialBrazilian Registry of Clinical Trials (ReBEC RBR-3bhbrb5, UTN code: U1111-1275-6679)Funding StatementYesAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical committee of the Federal University of Pará (CEP: 3.965.311/ CAAE: 27811119.4.0000.0018)I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.Not ApplicableAll relevant data are within the manuscript and its Supporting Information files.